Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Noemi Puig

Showing results (71-80 of 81) with videos related to

Pageof 9
Sort By:
The Lancet. Oncology|May 2, 2024
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myelomaPaula Rodriguez-Otero, Saad Usmani, Adam D Cohen, et al.
Blood|June 16, 2021
Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell developmentDaniel Alameda, Ibai Goicoechea, Marco Vicari, et al.
Blood Cancer Journal|May 22, 2021
Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trialNoemi Puig, Miguel T Hernández, Laura Rosiñol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 27, 2019
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple MyelomaBruno Paiva, Noemi Puig, Maria-Teresa Cedena, et al.
Blood|June 11, 2025
High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trialJuan-Jose Lahuerta, Jesús F San-Miguel, Ana Jiménez-Ubieto, et al.
The Journal of Pathology|February 22, 2018
Richter transformation driven by Epstein-Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemiaMaria J García-Barchino, Maria E Sarasquete, Carlos Panizo, et al.
Nature Communications|September 20, 2023
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistanceCirino Botta, Cristina Perez, Marta Larrayoz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2023
Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal GammopathiesLeire Burgos, Luis-Esteban Tamariz-Amador, Noemi Puig, et al.
Blood|July 22, 2020
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myelomaIbai Goicoechea, Noemi Puig, Maria-Teresa Cedena, et al.
Blood|January 29, 2026
Immune biomarkers of increased infection risk in multiple myelomaAintzane Zabaleta, Luis-Esteban Tamariz-Amador, Ioannis V Kostopoulos, et al.
Pageof 9

Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
The Lancet. Oncology|May 2, 2024
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myelomaPaula Rodriguez-Otero, Saad Usmani, Adam D Cohen, et al.
Blood|June 16, 2021
Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell developmentDaniel Alameda, Ibai Goicoechea, Marco Vicari, et al.
Blood Cancer Journal|May 22, 2021
Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trialNoemi Puig, Miguel T Hernández, Laura Rosiñol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 27, 2019
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple MyelomaBruno Paiva, Noemi Puig, Maria-Teresa Cedena, et al.
Blood|June 11, 2025
High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trialJuan-Jose Lahuerta, Jesús F San-Miguel, Ana Jiménez-Ubieto, et al.
The Journal of Pathology|February 22, 2018
Richter transformation driven by Epstein-Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemiaMaria J García-Barchino, Maria E Sarasquete, Carlos Panizo, et al.
Nature Communications|September 20, 2023
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistanceCirino Botta, Cristina Perez, Marta Larrayoz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2023
Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal GammopathiesLeire Burgos, Luis-Esteban Tamariz-Amador, Noemi Puig, et al.
Blood|July 22, 2020
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myelomaIbai Goicoechea, Noemi Puig, Maria-Teresa Cedena, et al.
Blood|January 29, 2026
Immune biomarkers of increased infection risk in multiple myelomaAintzane Zabaleta, Luis-Esteban Tamariz-Amador, Ioannis V Kostopoulos, et al.
Pageof 9